InnoCare Starts US Trial of BTK Inhibitor for MS
November 02, 2020 at 05:46 AM EST
Beijing 's InnoCare Pharma was approved to start a US Phase II trial of orelabrutinib, a Bruton’s tyrosine kinase inhibitor, in patients with multiple sclerosis. The trial will enroll 160 patients with relapsing-remitting MS in the US and several EU countries. Orelabrutinib is already being tested in the US and China as a treatment for B-cell lymphomas and autoimmune indications as a monotherapy or in combination regimens. InnoCare says it has shown efficacy with an ability to cross the blood-brain barrier. More details.... Stock Symbol: (HK: 09969) Share this with colleagues: // //